Kiniksa Pharmaceuticals International, plc — Form 10-Q
Filed July 28, 2026 · analyzed by the Periodic Agent
10-Q
— Neutral
significance 28/100
What the filing says
Dhiraj Malkani hired as Executive Vice President, Chief Strategy Officer (effective June 29, 2026) at $621,000 annual base salary plus 55% target bonus; separately, Eben Tessari transitioned from employment to consulting (effective May 15, 2026) at $450/hour, capped at $120,000/year. Both arrangements include standard severance, equity acceleration, and restrictive covenants. No material dollar impact quantified beyond routine compensation.
Why this rating
Routine executive hiring and employee-to-consultant transition. Malkani comp ~0.06% of $1.1B market cap; Tessari cap ~0.01%. No business-altering deals, strategic shifts, or asset/liability changes disclosed.
See more from July 28, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.